A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949 · Sjögren's Syndrome
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
PhasePhase 3
TypeInterventional
Age18 Years
WhereAvondale, Arizona, United States + 167 more
SponsorAmgen
▾Tap for detailsClick for full details — eligibility, all locations, contacts
168 sitesApply